TN2010000288A1 - 4-(4-cyano-2-thioaryl) dihydropyrimidines and use thereof - Google Patents

4-(4-cyano-2-thioaryl) dihydropyrimidines and use thereof

Info

Publication number: TN2010000288A1
Authority: TN; Tunisia
Prior art keywords: thioaryl; cyano; disorders; prevention; treatment
Prior art date: 2007-12-20

Application number

TN2010000288A

Other languages

English (en)

Inventor

Nussbaum Franz Von

Dagmar Karthaus

Sonja Anlauf

Martina Delbeck

Volkhart Min-Jian Li

Daniel Meibom

Klemens Lustig

Jens Schamberger

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-20

Filing date

2010-06-18

Publication date

2011-11-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40394273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000288(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-20 Priority claimed from DE102007061766A external-priority patent/DE102007061766A1/de

2008-05-07 Priority claimed from DE102008022521A external-priority patent/DE102008022521A1/de

2008-10-17 Priority claimed from DE102008052013A external-priority patent/DE102008052013A1/de

2010-06-18 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2011-11-11 Publication of TN2010000288A1 publication Critical patent/TN2010000288A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TN2010000288A 2007-12-20 2010-06-18 4-(4-cyano-2-thioaryl) dihydropyrimidines and use thereof TN2010000288A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DE102007061766A DE102007061766A1 (de)	2007-12-20	2007-12-20	4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102008022521A DE102008022521A1 (de)	2008-05-07	2008-05-07	1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
DE102008052013A DE102008052013A1 (de)	2008-10-17	2008-10-17	4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
PCT/EP2008/010411 WO2009080199A1 (fr)	2007-12-20	2008-12-09	4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation

Publications (1)

Publication Number	Publication Date
TN2010000288A1 true TN2010000288A1 (en)	2011-11-11

Family

ID=40394273

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000288A TN2010000288A1 (en)	2007-12-20	2010-06-18	4-(4-cyano-2-thioaryl) dihydropyrimidines and use thereof

Country Status (39)

Country	Link
US (3)	US8288402B2 (fr)
EP (1)	EP2234985B1 (fr)
JP (1)	JP5519526B2 (fr)
KR (2)	KR101712786B1 (fr)
CN (2)	CN101903356B (fr)
AR (1)	AR069765A1 (fr)
AT (1)	ATE548355T1 (fr)
AU (1)	AU2008340733B9 (fr)
BR (1)	BRPI0821027B8 (fr)
CA (1)	CA2709786C (fr)
CL (1)	CL2008003691A1 (fr)
CO (1)	CO6280490A2 (fr)
CR (1)	CR11472A (fr)
CY (1)	CY1112813T1 (fr)
DK (1)	DK2234985T3 (fr)
DO (1)	DOP2010000165A (fr)
EC (1)	ECSP10010216A (fr)
ES (1)	ES2382143T3 (fr)
HK (2)	HK1146485A1 (fr)
HR (1)	HRP20120457T1 (fr)
IL (2)	IL205742A (fr)
JO (1)	JO2756B1 (fr)
MA (1)	MA31920B1 (fr)
MX (1)	MX2010006033A (fr)
MY (1)	MY150285A (fr)
NZ (1)	NZ586263A (fr)
PE (1)	PE20091429A1 (fr)
PL (1)	PL2234985T3 (fr)
PT (1)	PT2234985E (fr)
RS (1)	RS52270B (fr)
RU (1)	RU2497813C2 (fr)
SG (2)	SG10201604819TA (fr)
SI (1)	SI2234985T1 (fr)
SV (1)	SV2010003581A (fr)
TN (1)	TN2010000288A1 (fr)
TW (1)	TWI455715B (fr)
UY (1)	UY31526A1 (fr)
WO (1)	WO2009080199A1 (fr)
ZA (1)	ZA201004239B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5672699B2 (ja) *	2007-04-11	2015-02-18	味の素株式会社	血糖降下作用化合物のスクリーニング法
CN101903356B (zh) *	2007-12-20	2013-05-22	拜耳知识产权有限责任公司	4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
DE102009016553A1 (de) *	2009-04-06	2010-10-07	Bayer Schering Pharma Aktiengesellschaft	Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung
GB201004179D0 (en) *	2010-03-12	2010-04-28	Pulmagen Therapeutics Inflamma	Enzyme inhibitors
GB201004178D0 (en) *	2010-03-12	2010-04-28	Pulmagen Therapeutics Inflamma	Enzyme inhibitors
DE102010030187A1 (de)	2010-06-16	2011-12-22	Bayer Schering Pharma Aktiengesellschaft	4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
BR112014003989A2 (pt)	2011-08-26	2017-06-13	Sanford-Burnham Medical Res Inst	composto, composições e métodos para inibir a replicação do hiv-1 em paciente, para tratar pacientes infectados com hiv/aids e para profilaxia de pré-exposição para tratar paciente e para prevenir a transmissão de pessoa infectada para pessoa não infectada
CN103373951B (zh) *	2012-04-28	2016-03-09	上海医药工业研究院	一种拉帕替尼中间体的制备方法
CN109568319A (zh)	2013-01-10	2019-04-05	普尔莫凯恩股份有限公司	非选择性激酶抑制剂
US20140221335A1 (en) *	2013-02-06	2014-08-07	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en)	2013-03-04	2015-08-25	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
JP6483714B2 (ja)	2013-10-11	2019-03-13	ローレンスエス．ジスマン，	噴霧乾燥製剤
USRE47493E1 (en)	2014-02-20	2019-07-09	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2015150362A2 (fr)	2014-04-03	2015-10-08	Bayer Pharma Aktiengesellschaft	Dérivés chiraux d'acide cyclopentanecarboxylique à disubstitution 2,5 et leur utilisation
EP3126339A1 (fr)	2014-04-03	2017-02-08	Bayer Pharma Aktiengesellschaft	Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation
JP2017509665A (ja)	2014-04-03	2017-04-06	バイエルファーマアクチエンゲゼルシャフト	気道疾患治療のための２，５−ジ置換されたシクロペンタンカルボン酸類
US9440930B2 (en) *	2014-07-31	2016-09-13	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en)	2014-07-31	2017-05-23	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) *	2014-07-31	2016-10-25	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) *	2014-07-31	2016-10-04	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) *	2014-07-31	2016-03-22	Boehringer Ingelheim International Gmbh	Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016050835A2 (fr) *	2014-10-02	2016-04-07	Ruprecht-Karls-Universität Heidelberg	Inhibiteurs sélectifs de l'élastase neutrophilique pour traiter des états de douleur neuropathique et de douleur chronique comprenant une composante neuropathique
EP3271337B1 (fr)	2015-03-18	2021-03-03	pH Pharma Co., Ltd.	Procédé de préparation de (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidin-5-carbonitrile
WO2016176399A1 (fr) *	2015-04-28	2016-11-03	Stc.Unm	Compositions et méthodes pour le traitement de l'hypertension pulmonaire
KR20180074793A (ko)	2015-11-13	2018-07-03	바이엘 파마 악티엔게젤샤프트	만성 상처 치료를 위한 4-(4-시아노-2-티오아릴)다이하이드로피리미디논
US10231966B2 (en)	2016-10-27	2019-03-19	Pulmokine, Inc.	Combination therapy for treating pulmonary hypertension
US9856232B1 (en)	2017-06-20	2018-01-02	King Saud University	Dihydropyrimidinone derivatives
EP3784657A4 (fr) *	2018-04-24	2022-02-09	pH Pharma Co., Ltd.	Utilisation d'inhibiteurs d'élastase neutrophile dans une maladie hépatique
GB201820450D0 (en) *	2018-12-14	2019-01-30	Z Factor Ltd	Compound and its use for the treatment of alpha1-antitryspin deficiency
CA3151997A1 (fr) *	2019-08-23	2021-03-04	Ph Pharma Co., Ltd.	Utilisation d'un inhibiteur de l'elastase neutrophile dans les maladies pulmonaires
CN111978179A (zh) *	2020-08-27	2020-11-24	青岛科技大学	一种6-羟基己酸酯的合成方法
WO2022076881A1 (fr) *	2020-10-09	2022-04-14	The Regents Of The University Of California	Méthodes de traitement de la maladie d'alzheimer à l'aide d'inhibiteurs d'époxyde hydrolase soluble à liaison étroite lents

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUT42077A (en) *	1985-06-03	1987-06-29	Squibb & Sons Inc	Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters
US4738965A (en) *	1987-02-03	1988-04-19	Institut Organischskogo Sinteza Akademii Nauk Ssr	2-oxo-4-(2'-difluoromethylthiophenyl)-5-methoxycarbonyl-6-methyl-1,2,3,4-tetrahydropyrimidine
GB9214053D0 (en) *	1992-07-02	1992-08-12	Ici Plc	Heterocyclic amides
US6235760B1 (en) *	1996-03-25	2001-05-22	Smithkline Beecham Corporation	Treatment for CNS injuries
SK2512002A3 (en) *	1999-08-19	2002-07-02	Nps Pharma Inc	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
GB0219896D0 (en) *	2002-08-27	2002-10-02	Bayer Ag	Dihydropyridine derivatives
WO2004024700A1 (fr) *	2002-09-10	2004-03-25	Bayer Healthcare Ag	Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires, ischemiques et de remodelage aigus et chroniques
GB2392910A (en) *	2002-09-10	2004-03-17	Bayer Ag	2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
AU2003255492A1 (en) *	2002-09-10	2004-04-30	Bayer Healthcare Ag	Heterocyclic derivatives
US7166603B2 (en)	2003-07-23	2007-01-23	Bristol-Myers Squibb Co.	Dihydropyrimidone inhibitors of calcium channel function
JP4825195B2 (ja) *	2004-02-26	2011-11-30	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	１，４−ジアリール−ジヒドロピリミジン−２オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
WO2005082864A1 (fr) *	2004-02-26	2005-09-09	Bayer Healthcare Ag	1,4-diaryl-dihydropyrimidin-2-ones et leur utilisation en tant qu'inhibiteurs de l'elastase du neutrophile humaine
JP2007530690A (ja) *	2004-03-29	2007-11-01	メルク　エンド　カムパニー　インコーポレーテッド	１１−β−ヒドロキシステロイドデヒドロゲナーゼ−１の阻害剤としてのジアリールトリアゾール
GB0502258D0 (en)	2005-02-03	2005-03-09	Argenta Discovery Ltd	Compounds and their use
GB0512940D0 (en)	2005-06-24	2005-08-03	Argenta Discovery Ltd	Compounds and their use
GB0520743D0 (en)	2005-10-12	2005-11-23	Argenta Discovery Ltd	Compounds and their use
EA018061B1 (ru)	2006-05-04	2013-05-30	Пульмаджен Терапьютикс (Инфлэмэйшн) Лимитед	Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
US20100010024A1 (en) *	2006-07-01	2010-01-14	Bayer Healthcare Ag	Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension
WO2008030158A1 (fr)	2006-09-04	2008-03-13	Astrazeneca Ab	Composés hétérocycliques multimériques utilisés comme inhibiteurs de l'élastase neutrophile
CN101903356B (zh) *	2007-12-20	2013-05-22	拜耳知识产权有限责任公司	4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
DE102008022521A1 (de) *	2008-05-07	2009-11-12	Bayer Schering Pharma Aktiengesellschaft	1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
DE102009016553A1 (de) *	2009-04-06	2010-10-07	Bayer Schering Pharma Aktiengesellschaft	Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung

2008
- 2008-12-09 CN CN2008801216561A patent/CN101903356B/zh active Active
- 2008-12-09 NZ NZ586263A patent/NZ586263A/en unknown
- 2008-12-09 EP EP08864824A patent/EP2234985B1/fr active Active
- 2008-12-09 MY MYPI2010002687A patent/MY150285A/en unknown
- 2008-12-09 SG SG10201604819TA patent/SG10201604819TA/en unknown
- 2008-12-09 US US12/809,781 patent/US8288402B2/en not_active Expired - Fee Related
- 2008-12-09 CA CA2709786A patent/CA2709786C/fr active Active
- 2008-12-09 SG SG2012094132A patent/SG186679A1/en unknown
- 2008-12-09 ES ES08864824T patent/ES2382143T3/es active Active
- 2008-12-09 BR BRPI0821027A patent/BRPI0821027B8/pt active IP Right Grant
- 2008-12-09 SI SI200830619T patent/SI2234985T1/sl unknown
- 2008-12-09 AT AT08864824T patent/ATE548355T1/de active
- 2008-12-09 DK DK08864824.1T patent/DK2234985T3/da active
- 2008-12-09 RS RS20120213A patent/RS52270B/en unknown
- 2008-12-09 RU RU2010129724/04A patent/RU2497813C2/ru active
- 2008-12-09 CN CN201310122598.7A patent/CN103204815B/zh active Active
- 2008-12-09 PL PL08864824T patent/PL2234985T3/pl unknown
- 2008-12-09 JP JP2010538407A patent/JP5519526B2/ja active Active
- 2008-12-09 KR KR1020167021839A patent/KR101712786B1/ko active IP Right Grant
- 2008-12-09 PT PT08864824T patent/PT2234985E/pt unknown
- 2008-12-09 AU AU2008340733A patent/AU2008340733B9/en active Active
- 2008-12-09 MX MX2010006033A patent/MX2010006033A/es active IP Right Grant
- 2008-12-09 KR KR1020107016069A patent/KR101649381B1/ko active Application Filing
- 2008-12-09 WO PCT/EP2008/010411 patent/WO2009080199A1/fr active Application Filing
- 2008-12-11 CL CL2008003691A patent/CL2008003691A1/es unknown
- 2008-12-11 UY UY31526A patent/UY31526A1/es active IP Right Grant
- 2008-12-11 PE PE2008002054A patent/PE20091429A1/es active IP Right Grant
- 2008-12-15 AR ARP080105447A patent/AR069765A1/es active IP Right Grant
- 2008-12-18 JO JO2008569A patent/JO2756B1/en active
- 2008-12-19 TW TW097149556A patent/TWI455715B/zh not_active IP Right Cessation
2010
- 2010-05-13 IL IL205742A patent/IL205742A/en active IP Right Grant
- 2010-05-28 EC EC2010010216A patent/ECSP10010216A/es unknown
- 2010-06-02 DO DO2010000165A patent/DOP2010000165A/es unknown
- 2010-06-02 SV SV2010003581A patent/SV2010003581A/es unknown
- 2010-06-02 CR CR11472A patent/CR11472A/es unknown
- 2010-06-02 CO CO10066579A patent/CO6280490A2/es not_active Application Discontinuation
- 2010-06-15 ZA ZA2010/04239A patent/ZA201004239B/en unknown
- 2010-06-16 MA MA32921A patent/MA31920B1/fr unknown
- 2010-06-18 TN TN2010000288A patent/TN2010000288A1/fr unknown
2011
- 2011-01-21 HK HK11100646.5A patent/HK1146485A1/xx not_active IP Right Cessation
2012
- 2012-05-29 HR HRP20120457AT patent/HRP20120457T1/hr unknown
- 2012-05-31 CY CY20121100495T patent/CY1112813T1/el unknown
- 2012-09-12 US US13/612,435 patent/US8889700B2/en active Active
2013
- 2013-09-02 HK HK13110227.9A patent/HK1183018A1/xx not_active IP Right Cessation
2014
- 2014-10-23 US US14/522,510 patent/US9174997B2/en active Active
- 2014-11-18 IL IL235754A patent/IL235754A/en active IP Right Grant

Also Published As

Publication number	Publication date
HRP20120457T1 (hr)	2012-06-30
ZA201004239B (en)	2011-10-26
US20110034433A1 (en)	2011-02-10
RU2497813C2 (ru)	2013-11-10
SG186679A1 (en)	2013-01-30
UY31526A1 (es)	2009-08-03
MA31920B1 (fr)	2010-12-01
ECSP10010216A (es)	2010-07-30
EP2234985A1 (fr)	2010-10-06
EP2234985B1 (fr)	2012-03-07
BRPI0821027B1 (pt)	2020-11-10
ATE548355T1 (de)	2012-03-15
US9174997B2 (en)	2015-11-03
JO2756B1 (en)	2014-03-15
MY150285A (en)	2013-12-31
HK1183018A1 (en)	2013-12-13
MX2010006033A (es)	2010-07-16
JP5519526B2 (ja)	2014-06-11
US8288402B2 (en)	2012-10-16
IL235754A (en)	2016-06-30
CA2709786C (fr)	2016-07-05
CR11472A (es)	2010-11-12
WO2009080199A1 (fr)	2009-07-02
AU2008340733A1 (en)	2009-07-02
PL2234985T3 (pl)	2012-08-31
CN103204815A (zh)	2013-07-17
AU2008340733B2 (en)	2014-01-30
BRPI0821027A2 (pt)	2015-06-16
HK1146485A1 (fr)	2011-06-10
PT2234985E (pt)	2012-05-17
US20140045802A1 (en)	2014-02-13
DK2234985T3 (da)	2012-06-25
RS52270B (en)	2012-10-31
NZ586263A (en)	2012-06-29
TW200940063A (en)	2009-10-01
JP2011506503A (ja)	2011-03-03
BRPI0821027B8 (pt)	2021-05-25
IL205742A0 (en)	2010-11-30
CL2008003691A1 (es)	2010-02-12
US8889700B2 (en)	2014-11-18
SG10201604819TA (en)	2016-07-28
SI2234985T1 (sl)	2012-06-29
US20150045344A1 (en)	2015-02-12
AR069765A1 (es)	2010-02-17
KR20100098710A (ko)	2010-09-08
ES2382143T3 (es)	2012-06-05
CO6280490A2 (es)	2011-05-20
RU2010129724A (ru)	2012-01-27
SV2010003581A (es)	2011-02-21
TWI455715B (zh)	2014-10-11
KR101649381B1 (ko)	2016-08-19
CA2709786A1 (fr)	2009-07-02
KR101712786B1 (ko)	2017-03-06
CN101903356B (zh)	2013-05-22
IL205742A (en)	2014-12-31
CY1112813T1 (el)	2016-02-10
PE20091429A1 (es)	2009-09-26
KR20160099733A (ko)	2016-08-22
AU2008340733B9 (en)	2014-03-06
CN101903356A (zh)	2010-12-01
CN103204815B (zh)	2015-01-28
DOP2010000165A (es)	2010-07-31

Publication	Publication Date	Title
TN2010000288A1 (en)	2011-11-11	4-(4-cyano-2-thioaryl) dihydropyrimidines and use thereof
UA102238C2 (en)	2013-06-25	4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
MY156777A (en)	2016-03-31	Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
TN2012000428A1 (en)	2014-01-30	Bisaryl-bonded aryltriazolones and use thereof
UA102065C2 (en)	2013-06-10	Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
TN2012000549A1 (en)	2014-04-01	Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
TW200724532A (en)	2007-07-01	Pyrimidinecarboxylic acid derivatives and their use
TW200736213A (en)	2007-10-01	Dicarboxylic acid derivatives and their use
WO2007127505A3 (fr)	2007-12-27	Composés chimiques
TW200800968A (en)	2008-01-01	Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2012076466A3 (fr)	2012-08-30	Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
WO2009068214A3 (fr)	2009-08-20	Pipéridines à substitution hétéroaryl
MY169564A (en)	2019-04-22	Substituted dihydropyrazolones and their use
WO2007125105A3 (fr)	2008-04-10	Activateurs de la glucokinase benzamidique
WO2008046581A3 (fr)	2008-06-12	Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
DK3045456T3 (da)	2018-01-29	Bicyklisk substituerede uraciler og anvendelse heraf
TW200621765A (en)	2006-07-01	Substituted phenylaminothiazoles and their use
MY150931A (en)	2014-03-14	Substituted oxazolidinones and their use
TW200745132A (en)	2007-12-16	Novel, acyclically substituted furopyrimidine derivatives and use thereof
WO2010115125A3 (fr)	2011-02-17	Composition à base de 2,4,6-trifluoro-n-[6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide
WO2006089664A3 (fr)	2006-11-02	Imidazoles substitues par heterocyclylamide
MX2010002506A (es)	2010-03-26	Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
CL2008000982A1 (es)	2008-10-10	Compuestos derivados de 5-oxo-isoxazol-carboxamida; proceso de preparacion; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de
MX2013002261A (es)	2013-05-22	N-fenetiltriazolonacetamidas sustituidas y su uso.
TN2010000266A1 (en)	2011-11-11	Oxazolidinones for the treatment and/or prophylaxis of heart failure